D. Clark

发表

Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease

R. Gearry, P. Hansen, M. Barclay, 2012, PharmacoEconomics.

Nose bleeds associated with use of risperidone

M. Harrison‐Woolrych, D. Clark, 2004, BMJ : British Medical Journal.

Monitoring the safety of over the counter drugs

S. Shakir, D. Layton, D. Clark, 2001, BMJ : British Medical Journal.

CNS Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs

D. Clark, A. Morgan, Althea Morgan, 1998, CNS drugs.

Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding?

S. Shakir, D. Layton, G. Pearce, 2001, European Journal of Clinical Pharmacology.

Genetically Determined Variability in Acetylation and Oxidation

D. Clark, 1985, Drugs.

Adverse Drug Reaction Reporting and Retrospective Phenotyping for Oxidation Polymorphism

I. Edwards, D. Clark, 1988, Medical toxicology and adverse drug experience.

Blood Pressure and Vascular Resistance in Genetically Hypertensive Rats Treated at Birth with 6‐Hydroxydopamine

D. Jones, D. Clark, C. Devine, 1978, Circulation research.

Adverse effects from metoprolol are not generally associated with oxidation status.

H. Waal-Manning, D. Clark, A. Morgan, 1984, British journal of clinical pharmacology.

Long‐lasting peripheral and central effects of 6‐hydroxydopamine in rats

R. Laverty, D. Clark, E. L. Phelan, 1972, British journal of pharmacology.

QT interval prolongation associated with sibutramine treatment.

J. Skinner, M. Harrison‐Woolrych, M. Rees, 2006, British journal of clinical pharmacology.

Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?

D. Clark, J. Strandell, 2006, European Journal of Clinical Pharmacology.

Genetically determined variability in acetylation and oxidation. Therapeutic implications.

D. Clark, 1985, Drugs.

Neuropsychiatric Reactions to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

D. Clark, K. Ghose, 1992, Drug safety.

Effects of Immunosympathectomy on Development of High Blood Pressure in Genetically Hypertensive Rats

D. Clark, 1971, Circulation research.

The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.

M. Harrison‐Woolrych, D. Clark, 2006, Current drug safety.

Changes in rat hind limb vascular resistance following intracerebroventricular drug administration.

D. Clark, J. Elliott, 1977, European journal of pharmacology.

Specific noradrenergic neurones destroyed by 6-hydroxydopamine injection into newborn rats.

K. Taylor, R. Laverty, D. Clark, 1972, Nature: New biology.

Variability in the elimination of mianserin in elderly patients.

R. Sainsbury, E. Begg, D. Clark, 1989, British journal of clinical pharmacology.

Vasodilator responses to K+ in genetic hypertensive and in renal hypertensive rats.

D. Clark, H. W. Overbeck, 1975, The Journal of laboratory and clinical medicine.

Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology

D. Clark, D. Coulter, Althea Morgan, 2000, Pharmacoepidemiology and drug safety.

Linking Pharmacovigilance with Pharmacogenetics

D. Coulter, M. Kennedy, R. Roberts, 2004, Drug safety.

Clinical Implications of Pharmacogenetic Variation on the Effects of Statins

M. Kennedy, S. Maggo, D. Clark, 2011, Drug safety.

Profiles of Hepatic and Dysrhythmic Cardiovascular Events Following Use of Fluoroquinolone Antibacterials

S. Shakir, D. Layton, L. Wilton, 2001, Drug safety.

The effect of statins on performance in the Morris water maze in guinea pig.

S. Maggo, D. Clark, J. Ashton, 2012, European journal of pharmacology.

Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.

S. Shakir, D. Layton, G. Pearce, 2001, European journal of clinical pharmacology.

Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?

S. Shakir, D. Layton, D. Clark, 2004, Drug safety.

Randomized Controlled Trials and Assessment of Drug Safety

D. Coulter, F. Besag, D. Clark, 2008, Drug safety.

Psoriasis associated with rofecoxib.

D. Coulter, D. Clark, 2003, Archives of Dermatology.

Nose bleeds associated with use of risperidone

M. Harrison‐Woolrych, D. Clark, 2004, BMJ : British Medical Journal.

A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).

D. Coulter, Sheila M. Williams, S. Williams, 1999, British journal of clinical pharmacology.

Peripheral Cardiovascular Effects in Rats after Central Administration of Histamine and Antihistamines

D. Clark, G. J. Carroll, 1979, Clinical and experimental pharmacology & physiology.

Sibutramine may be associated with memory impairment

M. Harrison‐Woolrych, D. Clark, 2004, BMJ : British Medical Journal.